Dulcinea Quintana, MD
Internal Medicine · Albuquerque, NMNPI 1912046921
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Genentech USA, Inc. accounts for 63.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $124 and has fallen 56.1% since, to $54 in 2025.
Across 3 payments — averaging $64.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$124
- Novartis$54
- Merck$16
Across 10 payments — averaging $15,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$133K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Food & beverage$17892%
- Education$168%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $124 |
| Novartis | 1 | $54 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$124
How this compares
$193 in reported general payments places this provider in the 65th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 40 | $711,452 |
| RevlimidLenalidomide | 17 | $366,298 |
| PomalystPomalidomide | 15 | $344,300 |
| Lenalidomide | 17 | $246,121 |
| BosulifBosutinib | 12 | $232,618 |
| XareltoRivaroxaban | 13 | $17,737 |
| EliquisApixaban | 15 | $15,954 |
| Hydroxyurea | 42 | $1,258 |
| Sirolimus | 11 | $780 |
| Ventolin HfaAlbuterol Sulfate | 14 | $778 |
| Acyclovir | 44 | $718 |
| Dexamethasone | 18 | $290 |
| Ondansetron Hcl | 11 | $209 |
| Gabapentin | 21 | $200 |
| Oxycodone Hcl | 12 | $190 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Albuquerque
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.